Thousands of individuals living with primary immunodeficiency diseases, including Chronic Granulomatous Disease (CGD), go undiagnosed. They face frequent health problems and suffer from serious, debilitating illnesses that go on undetected and untreated.
As a biopharmaceutical company committed to improving patients' lives by addressing unmet medical needs, Horizon Pharma recently debuted a new program with Good Days that empowers patients with financial needs to see if they are eligible for financial support to receive Dihyrorhodamine (DHR) testing – a diagnostic screening for CGD administered in laboratories and larger medical centers.
If you, your child or someone you care for presents signs and symptoms consistent with CGD, your physician can submit a Service Request Form (SRF) to the patient support system TranscendRare to initiate the benefits investigation and see if you or the patient you care for is eligible for financial assistance with DHR testing.
Whether a patient has zero insurance coverage, co-pays or deductibles for in and out-of-network lab testing, DHR financial assistance may be available. Upon receiving a SRF form for a patient, a TranscendRare Program Coordinator will assess a patient’s eligibility based on predetermined qualifying requirements set by Good Days (formerly known as the Chronic Disease Fund), the foundation supporting this program.
To learn more about this program, reach out to a TranscendRare Program Coordinator at (877) 305-7704.